Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HORIZON PHARMA INC

SummaryNewsRatingsCalendarCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

With eye on tax rates, Horizon Pharma buys Ireland's Vidara

03/19/2014 | 10:06am EDT

(Reuters) - Horizon Pharma Inc (>> Horizon Pharma Inc) said it would buy Dublin-based Vidara Therapeutics International Ltd in a reverse merger for $660 million (ú397.09 million), the latest U.S. company looking to benefit from Ireland's low corporate tax rates.

(Reuters) - Horizon Pharma Inc (>> Horizon Pharma Inc) said it would buy Dublin-based Vidara Therapeutics International Ltd in a reverse merger for $660 million (£397.09 million), the latest U.S. company looking to benefit from Ireland's low corporate tax rates.

The company's shares rose 25 percent to a life-high of $18.30 in early trade as the deal also boosts its pipeline.

Horizon CEO Timothy Walbert said on a conference call that the combined company's tax rate would be in the low-20 percent range, or lower, compared to the high-30 percent range it expected earlier.

RF Lafferty & Co analyst Difei Yang said the deal makes sense as Horizon has said it would turn profitable this year.

"From this point forward, tax rate becomes an important consideration," she told Reuters, adding that she expected the rate to fall to a mid-teens percentage in two to three years.

Horizon has been reporting losses since going public in 2011.

The deal adds Vidara's genetic disorder drug Actimmune to Horizon's portfolio of four drugs used to treat different forms of arthritis.

Analyst Difei Yang said Horizon could use its strength in marketing to boost sales of Actimmune, which she said was "underpromoted".

The drug, which was sold to Vidara by Intermune Inc (>> InterMune Inc) in 2012, generated sales of $58.9 million in 2013.

Cowen and Co analyst Edward Nash said Actimmune had a market potential of about $150 million to $200 million.

Walbert said Horizon would explore additional uses of Actimmune, but did not provide further details.

STOCK AND CASH

Horizon Pharma said on Wednesday the stock-and-cash deal would create a new company, Horizon Pharma Plc, which would be 26 percent owned by Vidara shareholders. They will also receive $200 million in cash.

Privately held Vidara has operations in Ireland and the United States.

The deal is the latest in a series of transactions structured by U.S. pharma companies to take advantage of Ireland's low tax rates.

U.S. drugmaker Perrigo Co Plc (>> Perrigo Company PLC) bought Irish firm Elan (>> Elan Corporation, plc) for $8.6 billion in December. Endo Health Solutions (>> Endo Health Solutions Inc) acquired Canadian drugmaker Paladin in a deal that created a new holding company based in Ireland that would own both firms.

Horizon Pharma Plc, which will be headed by Horizon CEO Timothy Walbert, is expected to generate pro-forma full-year revenue of $250 million-$265 million.

Horizon said it had secured a $250 million bridge loan funding from Deerfield Management Co LP.

Citigroup Global Markets Inc acted as lead financial adviser to Horizon Pharma and JMP Securities LLC served as co-financial adviser.

KPMG LLP served as Horizon's tax adviser and Cooley LLP and Dublin-based McCann FitzGerald were the legal advisors.

Horizon Pharma's shares were trading up about 17 percent at $17.14 in morning trading. About 8 million shares changed hands by 1050 ET, more than three times their 10-day moving average.

(Reporting by Vrinda Manocha in Bangalore; Editing by Sriraj Kalluvila)

By Vrinda Manocha


ę Reuters 2014
Stocks mentioned in the article
ChangeLast1st jan.
ELAN CORPORATION LTD -0.39% 12.71 End-of-day quote.0.00%
ENDO INTERNATIONAL PLC -3.85% 3.25 Delayed Quote.-54.74%
PERRIGO COMPANY PLC 0.54% 43 Delayed Quote.-3.85%
THE LEAD CO., INC. 11.30% 719 End-of-day quote.-14.40%
All news about HORIZON PHARMA INC
09/23INSIDER SELL : Horizon Therapeutics Public Ltd
MT
09/23HORIZON THERAPEUTICS PUBLIC : Says Uplizna May Provide Durable Efficacy for African Americ..
MT
09/23HORIZON THERAPEUTICS PUBLIC : áHorizon Therapeutics plc Announces Agenda for Virtual R&D D..
BU
09/23HORIZON THERAPEUTICS PLC : Announces Data Showing UPLIZNA« (inebilizumab-cdon) Also Produc..
BU
09/23Horizon Therapeutics Public Limited Company Announces Data Showing UPLIZNA Also Produce..
CI
09/21HORIZON THERAPEUTICS PUBLIC : Partner HemoShear Advancing Several Novel Compounds
MT
09/21HORIZON THERAPEUTICS PLC : Announces New Genetic Counselor Curated Algorithms and Next-Gen..
BU
09/21HEMOSHEAR THERAPEUTICS : Advancing Several Novel Compounds for Horizon Therapeutics plc Go..
PR
09/20INSIDER SELL : Horizon Therapeutics Public Ltd
MT
09/16HORIZON THERAPEUTICS PLC : Named One of the 2021 Best Workplaces for Women™ by Fortu..
BU
More news
Analyst Recommendations on HORIZON PHARMA INC
More recommendations
Managers and Directors
Timothy P. Walbert Chairman, President & Chief Executive Officer
Paul W. Hoelscher Chief Financial Officer & Executive Vice President
Jeffrey W. Sherman Chief Medical Officer & Executive Vice President
Jeffrey D. Kent Executive VP-Medical Affairs & Outcomes Research
Karin Rosen Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
HORIZON PHARMA INC24 932
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.20.05%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037